Medicare's national coverage procedures fail to deliver
This article was originally published in Clinica
Medicare's largely untested process for arriving at national coverage decisions has produced its first casualty. Laboratories offering human tumour drug sensitivity assays have withdrawn their formal request for a national coverage determination from the Health Care Financing Administration (HCFA), the agency that runs the US federal health plan for the elderly and the disabled.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.